(Q43785792)

26 November 2017

title

IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy (English)

1 reference

26 November 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

25 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

25 March 2024

author name string

J. W. Koten

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

M. J A. Van Luyn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

J. A. Cadée

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

L. Brouwer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

W. E. Hennink

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

C. Bijleveld

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

W. Den Otter

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580999

25 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14580999

25 March 2024

publication date

1 November 2003

1 reference

26 November 2017

7 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14580999

full work available at URL

25 March 2024

https://api.elsevier.com/content/article/PII:S1043466603002679?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

https://api.elsevier.com/content/article/PII:S1043466603002679?httpAccept=text/plain

25 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

25 March 2024

1 reference

26 November 2017

volume

24

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

57-66

1 reference

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Optimal regimes for local IL-2 tumour therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Release of recombinant human interleukin-2 from dextran-based hydrogels

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic)acid after subcutaneous injection in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

The preparation of dextran microspheres in an all-aqueous system: effect of the formulation parameters on particle characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Degradation kinetics of methacrylated dextrans in aqueous solution

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

The inflammatory potential of IL-2: local induction of a specific chronic granulomatous lesion in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Interleukin-2 and human monocyte activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-4666%2803%2900267-9

7 January 2021

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors

5

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

INTRAVESICAL INTERLEUKIN-2 IN T1 PAPILLARY BLADDER CARCINOMA: REGRESSION OF MARKER LESION IN 8 OF 10 PATIENTS

25 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)

25 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

Tumour regression by IL-2 mediated stagnation of blood flow

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

Human recombinant interleukin-2 as an experimental therapeutic

25 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/S1043-4666(03)00267-9

25 March 2024

Identifiers

1 reference

26 November 2017

1 reference